Scholarlink

Background <p>Juvenile neuronal ceroid lipofuscinosis (JNCL, Batten Disease) is a childhood-onset, neurodegenerative, lysosomal storage disorder caused by mutations in the lysosomal gene CLN3. Progressive cognitive decline is characteristic clinical feature, and no definitive treatment is currently available. The neuronal function of CLN3 is unknown, and the pathomechanisms leading to cognitive impairment are poorly understood hindering the development of targeted therapies.</p> Methods <p>Whole-cell patch clamp and high-density microelectrode array recordings were performed in acute brain slices from <i>Cln3</i><sup>Δex7/8</sup> mice to assess synaptic properties, intrinsic excitability, and network activity. High-resolution confocal imaging was used to quantify dendritic spine density. To explore pre- and postsynaptic roles of CLN3, adeno-associated viral (AAV) re-expression of <i>CLN3</i> was combined with optogenetics, allowing assessment of CLN3 function in each compartment selectively.</p> Results <p>Loss of CLN3 caused defective synaptic vesicle release and reduced synaptic strength, reflecting impairments in both pre- and postsynaptic function in <i>Cln3</i><sup>Δex7/8</sup> mice. We also observed reduced network bursting and deficits in intrinsic neuronal excitability, indicating early functional disturbances independent of storage burden and neuronal loss. Further, we report non-redundant requirements for CLN3 at both pre- and postsynaptic sites to sustain function. Importantly, AAV9-mediated gene rescue at early disease stages corrected preexisting synaptic defects and restored function.</p> Conclusions <p>Our findings demonstrate a critical requirement for CLN3 in maintaining synaptic function and show that targeted gene therapy can restore established functional deficits in <i>Cln3</i>-deficient mice. This suggests that the therapeutic window may extend to stages already characterized by functional impairments, raising hope that targeted interventions could not only slow disease progress but to also potentially restore neuronal function and thereby improve clinical outcome. Moreover, these early synaptic deficits provide sensitive and robust functional readouts that can support preclinical research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reversible synaptic deficits in early-stage batten disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月20日

查看全文
  • Masood Ahmad Wani,
  • Chloe M. Hall,
  • Thomas Mittmann,
  • Benedikt Grünewald,
  • Jakob von Engelhardt

摘要

Background

Juvenile neuronal ceroid lipofuscinosis (JNCL, Batten Disease) is a childhood-onset, neurodegenerative, lysosomal storage disorder caused by mutations in the lysosomal gene CLN3. Progressive cognitive decline is characteristic clinical feature, and no definitive treatment is currently available. The neuronal function of CLN3 is unknown, and the pathomechanisms leading to cognitive impairment are poorly understood hindering the development of targeted therapies.

Methods

Whole-cell patch clamp and high-density microelectrode array recordings were performed in acute brain slices from Cln3Δex7/8 mice to assess synaptic properties, intrinsic excitability, and network activity. High-resolution confocal imaging was used to quantify dendritic spine density. To explore pre- and postsynaptic roles of CLN3, adeno-associated viral (AAV) re-expression of CLN3 was combined with optogenetics, allowing assessment of CLN3 function in each compartment selectively.

Results

Loss of CLN3 caused defective synaptic vesicle release and reduced synaptic strength, reflecting impairments in both pre- and postsynaptic function in Cln3Δex7/8 mice. We also observed reduced network bursting and deficits in intrinsic neuronal excitability, indicating early functional disturbances independent of storage burden and neuronal loss. Further, we report non-redundant requirements for CLN3 at both pre- and postsynaptic sites to sustain function. Importantly, AAV9-mediated gene rescue at early disease stages corrected preexisting synaptic defects and restored function.

Conclusions

Our findings demonstrate a critical requirement for CLN3 in maintaining synaptic function and show that targeted gene therapy can restore established functional deficits in Cln3-deficient mice. This suggests that the therapeutic window may extend to stages already characterized by functional impairments, raising hope that targeted interventions could not only slow disease progress but to also potentially restore neuronal function and thereby improve clinical outcome. Moreover, these early synaptic deficits provide sensitive and robust functional readouts that can support preclinical research.